Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ: EXEL )

35.00 +0.51 (+1.48%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Investors should take notice of NASDAQ:EXEL—it offers a great deal for the fundamentals it presents.
EXELIXIS INC (NASDAQ:EXEL) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
Peering Into Exelixis's Recent Short Interest
Via Benzinga
Expert Outlook: Exelixis Through The Eyes Of 19 Analysts
Via Benzinga
This Match Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Via Benzinga
NASDAQ:EXEL is showing decent growth, but is still valued reasonably.
EXELIXIS INC (NASDAQ:EXEL) is showing good growth, while it is not too expensive. 
Via Chartmill
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U.S. payers. Discover key findings and trends. 
Via Benzinga
Earnings Preview: Exelixis
Via Benzinga
1 No-Brainer Stock to Buy With $40
The midcap biotech just became an even better buy. 
Via The Motley Fool
Analyst Ratings For Exelixis
Via Benzinga
2 Biotech Stocks to Buy Hand Over Fist in December
Via The Motley Fool
End Of Year Rally: 3 Stocks To Watch (InterDigital, Futu Holdings, Exelixis)
As the calendar winds down, the stock market often heats up. This 
Via Talk Markets
Topics Stocks / Equities
Ten Young Ones
Here are a variety of lesser-known charts from my “Recents” watch list. Quite a few of them look like good bullish plays. 
Via Talk Markets
Topics Stocks / Equities
NASDAQ:EXEL appears to be flying under the radar despite its strong fundamentals.
EXELIXIS INC (NASDAQ:EXEL): good value for what you're paying. 
Via Chartmill
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December
From Exelixis, Inc.
Via Business Wire
Navigating 16 Analyst Ratings For Exelixis
Via Benzinga
Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors
From Exelixis, Inc.
Via Business Wire
BioNTech Stock Got A IBD RS Rating Lift
A Relative Strength Rating upgrade for BioNTech ADR shows improving technical performance. 
Via Investor's Business Daily
Vericel Stock Sees RS Rating Shoot Higher
The Relative Strength (RS) Rating for Vericel stock entered a higher percentile Monday, as it got a lift from 69 to 79. 
Via Investor's Business Daily
NASDAQ:EXEL is an undervalued gem with solid fundamentals.
For those who appreciate value investing, EXELIXIS INC (NASDAQ:EXEL) is a compelling option with its solid fundamentals. 
Via Chartmill
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November
From Exelixis, Inc.
Via Business Wire
3 Magnificent Stocks Under $100 to Buy in November
The price could be right for these stocks. 
Via The Motley Fool
Reddit, Roblox And Garmin Are Among Top 10 Large Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio?
The top 10 performers last week were Reddit, Paycom, Mobileye, Exelixis, Garmin, Roblox, Twilio, Snap, Waters, and Atlassian. Many analysts raised price forecasts. 
Via Benzinga
Snap Posts Upbeat Earnings, Joins Unisys, AtriCure, Garmin And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Exelixis (EXEL) Q3 2024 Earnings Call Transcript
EXEL earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Biotech Momentum Trades For The Q4 Rally
The biotech sector made an interim peak in late February followed by an active summer in very choppy trading. 
Via Talk Markets
Momentum Has Narrowed Again, Significantly
It is more of a stock pickers market than usual as momentum factors are currently exaggerated. 
Via Talk Markets
In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals.
In a market where value is scarce, EXELIXIS INC (NASDAQ:EXEL) offers a refreshing opportunity with its solid fundamentals. 
Via Chartmill
Exelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Update on Second Patent Litigation Trial with MSN Laboratories
From Exelixis, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.